<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DC44A53-BE64-4D8A-98B2-A4FBFE5AC4A9"><gtr:id>2DC44A53-BE64-4D8A-98B2-A4FBFE5AC4A9</gtr:id><gtr:name>Crescendo Biologics Limited</gtr:name><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DC44A53-BE64-4D8A-98B2-A4FBFE5AC4A9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>2DC44A53-BE64-4D8A-98B2-A4FBFE5AC4A9</gtr:id><gtr:name>Crescendo Biologics Limited</gtr:name><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>137612.0</gtr:offerGrant><gtr:projectCost>197605.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6966A745-DB47-474F-BB8F-1DF820A1375B"><gtr:id>6966A745-DB47-474F-BB8F-1DF820A1375B</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:surname>McGuinness</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=132033"><gtr:id>1BD27F46-9682-4C3F-B18F-FD1836EF74CC</gtr:id><gtr:title>Next generation ADC therapeutics: Improved potency &amp;amp; safety for treating cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>132033</gtr:grantReference><gtr:abstractText>While mAb-based ADCs have shown good efficacy, there are currently only two approved by the FDA due to significant challenges associated with this product class including high production costs and off target toxicity. The Crescendo Mouse is a novel platform which generates the smallest potent human antibody fragments (Humabodies?). With a view to developing the next generation of toxin-conjugated products, we aim to establish a new class of VH-ADC therapeutics. Crescendo will achieve this by obtaining proof of concept data to validate an innovative therapeutic for prostate cancer to provide a much needed safe and effective treatment. Objectives are to manufacture the candidate Humabody-ADC, obtain in vitro and in vivo confirmation of efficacy and differentiation from existing mAb-ADC formats and establish the groundwork for a comprehensive preclinical project. This product will open the door to high value Humabody-toxin conjugate biologics for cancer Indications with unmet needs.</gtr:abstractText><gtr:fund><gtr:end>2016-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>137612</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">132033</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>